RRMS

Long-term treatment with Gilenya (fingolimod) in routine clinical practice is safe and effective for relapsing-remitting multiple sclerosis (RRMS), a five-year study in Germany of more than 4,000 patients reported. Over time, relapses in the majority of study patients who continued with Gilenya became less common and less severe,…

The ENSURE-2 Phase 3 clinical trial, evaluating Immunic Therapeutics’ experimental oral therapy IMU-838 (vidofludimus calcium) in adults with relapsing-remitting multiple sclerosis (RRMS), has enrolled its first patient. The milestone, announced in an email to Multiple Sclerosis News Today, follows the recruitment of the first RRMS patient in…

Emerald Health Pharmaceuticals will soon begin enrollment in a Phase 2a clinical trial investigating its cannabidiol-derived therapy EHP-101 in relapsing forms of multiple sclerosis (MS). The trial (NCT04909502) aims to recruit 50 patients, ages 18-55, with relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS).

Ocrevus (ocrelizumab) may be more effective than Gilenya (fingolimod) at preventing relapse in relapsing-remitting multiple sclerosis (RRMS) patients who recently transitioned from Tysabri (natalizumab), according to a new study. Ocrevus is “potentially a better exit strategy than [Gilenya] after [Tysabri] cessation, with an impressive reduction [in] risk…

A Phase 1 clinical trial investigating the safety and tolerability of Anokion‘s ANK-700 in people with relapsing-remitting multiple sclerosis (RRMS) has begun enrolling patients for its multiple ascending dose part. This opening of the study’s second part follows positive safety signs in patients given the one of two doses of…

Note: This story was updated Jan. 12, 2022, to note that Ponvory is approved in the U.K. for people with relapsing forms of MS who have active disease, defined by clinical or imaging features. The National Institute for Health and Care Excellence (NICE) has recommended that Ponvory (ponesimod)…

The U.S. Food and Drug Administration (FDA) has agreed to review TG Therapeutics’ application seeking the approval of ublituximab as a treatment for people with relapsing forms of multiple sclerosis. An FDA’s decision is expected on or before Sept. 28. The agency is not currently planning to hold an…

Tecfidera (dimethyl fumarate) and Aubagio (teriflunomide) are the preferred disease-modifying treatments for managing relapsing-remitting multiple sclerosis (RRMS) in Canada, according to a report from Spherix Global Insights. The report was part of Spherix’s RealTime Dynamix: Multiple Sclerosis (Canada) service, which collects data on market trends of MS…

“Shoes are the quickest way for women to achieve instant metamorphosis.” — Manolo Blahnik As the holidays approach, I’m reminded to be thankful for what I have. I was diagnosed with relapsing-remitting multiple sclerosis (RRMS) at 26 years old, and when I became paralyzed, I thought I’d never…

Immunic Therapeutics has enrolled the first participant in its Phase 3 ENSURE clinical trial program, which is testing the company’s investigational treatment IMU-838 (vidofludimus calcium) in people with relapsing-remitting multiple sclerosis (RRMS). “Enrollment of the first patient in ENSURE … marks an important inflection point for Immunic as we…

Long-term use of a high-dose nutritional supplement containing specific antioxidant vitamins and omega-3 and omega-6 fatty acids may boost walking performance and other measures of functional capacity in people with relapsing-remitting multiple sclerosis (RRMS), a new study found. The study, “The Effects of Specific Omega-3 and…

The oral medication Vumerity (diroximel fumarate) has been approved by the European Commission to treat adults with relapsing-remitting multiple sclerosis (RRMS). “This approval is a significant step forward in improving treatment adherence for people living with relapsing MS, which can make a meaningful difference on treatment…

The number of lesions affecting the cerebellum — a brain region responsible for coordinating voluntary movements and motor skills such as balance, coordination, and posture — predicts manual dexterity getting worse in people with relapsing-remitting multiple sclerosis (RRMS), according to a retrospective analysis. The study, “Cerebellar pathology and…

Most relapsing-remitting multiple sclerosis (RRMS) patients switching to Ocrevus (ocrelizumab) following suboptimal responses to other disease-modifying therapies (DMTs) show no evidence of disease activity, according to final two-year data from the European-based CASTING Phase 3b trial. These clinical benefits, which entail no relapses or disease progression and no…

The Scottish Medicines Consortium (SMC) has recommended that Ponvory (ponesimod) be offered through the National Health Service (NHS) Scotland to people with active, relapsing forms of multiple sclerosis (MS). The decision means that the oral therapy will be available at low or no cost to patients with clinically isolated syndrome (CIS),…

Measuring levels of the protein serum neurofilament light chain (NfL) can help to identify people with relapsing-remitting multiple sclerosis (RRMS) at higher risk of relapse-free disability progression or conversion to secondary-progressive disease, according to a study from Germany. The study, “NfL predicts relapse-free progression in a longitudinal…

I want to help in any way I possibly can. My lonely confusion in the early days after being diagnosed with aggressive relapsing-remitting multiple sclerosis was mentally and physically paralyzing. However, this column isn’t about how “Hurricane MS” battered my body. Instead, it’s about why I chose to…

Numares has signed an exclusive licensing agreement with Oxford University Innovation to develop and commercialize a panel of biomarkers that identify disease progression in people with multiple sclerosis (MS). Specifically, the company aims to create a tool that detects early signs of conversion from relapsing remitting…

National MS Society Supports Stem Cell Transplant for Select, Aggressive RRMS Bravo! This statement is welcome after the recommendation of National Multiple Sclerosis Society advisers that autologous hematopoietic stem cell transplant, or AHSCT, could be useful for people younger than 50 and recently diagnosed with MS. Now, how long…

A model that considers changes in brain volume and serum neurofilament (sNfL) levels during the early stages of multiple sclerosis may help clinicians to determine an individual’s likely progression with relapsing forms of MS, a study suggests. “We were able to build reliable, robust models capable of accurate predictions of…

The National Multiple Sclerosis Society supports the use of a patient-derived bone marrow transplant to treat people with very aggressive relapsing-remitting multiple sclerosis (RRMS) who responded poorly to disease-modifying therapies (DMTs). This position is in line with a recent set of society recommendations on how and in…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. People…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. Mavenclad…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. People with …

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the…

The U.S. Patent and Trademark Office will grant Medsenic a patent covering the use of Arscimed, its investigational formulation of arsenic trioxide, for the treatment of relapsing-remitting multiple sclerosis (RRMS). Once issued, the patent will protect Arscimed’s use for this indication until 2037. This will add to the already…

The National Institute for Health and Care Excellence (NICE) will not recommend that Ponvory (ponesimod) be added to the National Health Service (NHS) of England and Wales for people with active, relapsing forms of multiple sclerosis (MS). The provisional decision, made because Ponvory was not found to be…

I am having an MS relapse, my first in three years. In the first two years after I was diagnosed with relapsing-remitting MS in early 2017, I relapsed every two or three months. It got to the point that I couldn’t tell where one relapse began and another ended.

Treatment with evobrutinib, an experimental therapy for relapsing forms of multiple sclerosis (MS), reduced the size of inflammation-associated brain lesions in a Phase 2 clinical trial, data show. The oral medication was also found to be generally safe and well tolerated, according to an analysis of trial data in…

TG Therapeutics  has applied to the U.S. Food and Drug Administration (FDA) for approval of ublituximab, the company’s investigational anti-CD20 monoclonal antibody therapy for relapsing forms of multiple sclerosis (RMS). Its application was based on data from the ULTIMATE 1 (NCT03277261) and ULTIMATE 2 (NCT03277248) Phase…